Nantahala Capital Management, LLC

Position in FULC — Fulcrum Therapeutics, Inc.

CIK 1472322 New Canaan, CT

Position in FULC

as of Mar 31, 2026 · filed May 15, 2026 Compact

Position Value

$23,393,806

-$25,163,937 QoQ

Shares Held

3,050,040

-29.0% QoQ

Ownership

4.58%

of shares outstanding

% of Portfolio

1.47%

of 13F equity value

Holder Rank

of 168 holders

Holding Since

Dec 2022

10 quarters on record

Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Healthcare · as of Mar 31, 2026

Nantahala Capital Management, LLC holds $574,927,961 across 52 Biotechnology names. FULC ranks #7 (4.1% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	SLNO	Soleno Therapeutics Inc	1,744,124	$58,393,271
2	SVRA	Savara Inc	7,344,783	$40,102,515
3	TNGX	Tango Therapeutics, Inc.	1,250,452	$26,159,455
4	LBRX	Lb Pharmaceuticals Inc	1,052,894	$25,964,366
5	MLYS	Mineralys Therapeutics, Inc.	895,481	$24,258,580
6	ZVRA	Zevra Therapeutics, Inc.	2,521,936	$23,504,443
7	FULC	Fulcrum Therapeutics, Inc. This page	3,050,040	$23,393,806
8	ABEO	Abeona Therapeutics Inc.	5,013,052	$22,458,472

10 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$23,393,806	3,050,040	-29.0%	Shares	Sole	2026-05-15
2025-12-31	$48,557,743	4,293,346	-8.1%	Shares	Sole	2026-02-13
2025-09-30	$42,971,212	4,670,784	+8.9%	Shares	Sole	2025-11-14
2025-06-30	$29,503,497	4,288,299	-11.1%	Shares	Sole	2025-08-14
2025-03-31	$13,889,355	4,822,693	+0.9%	Shares	Sole	2025-05-15
2024-12-31	$22,464,627	4,779,708	+0.0%	Shares	Sole	2025-02-14
2024-09-30	$17,057,145	4,777,912	+22258.0%	Shares	Sole	2024-11-14
2023-06-30	$70,521	21,370	0.0%	Shares	Sole	2023-08-14
2023-03-31	$60,904	21,370	-95.7%	Shares	Sole	2023-05-15
2022-12-31	$3,640,000	500,000	—	Shares	Sole	2023-02-14
No filing history on record for this holder in this stock.